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Abstract
The mouse is the main model organism used to study the
functions of human genes because most biological processes in
the mouse are highly conserved in humans. Recent reports that
compared identical transcriptomic datasets of human inflamma-
tory diseases with datasets from mouse models using traditional
gene-to-gene comparison techniques resulted in contradictory
conclusions regarding the relevance of animal models for transla-
tional research. To reduce susceptibility to biased interpretation,
all genes of interest for the biological question under investiga-
tion should be considered. Thus, standardized approaches for
systematic data analysis are needed. We analyzed the same data-
sets using gene set enrichment analysis focusing on pathways
assigned to inflammatory processes in either humans or mice. The
analyses revealed a moderate overlap between all human and
mouse datasets, with average positive and negative predictive
values of 48 and 57% significant correlations. Subgroups of the
septic mouse models (i.e., Staphylococcus aureus injection) corre-
lated very well with most human studies. These findings support
the applicability of targeted strategies to identify the optimal
animal model and protocol to improve the success of translational
research.
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Introduction
The mouse has been used as model for heredity analysis since the
19th century. The development of targeted genetic modifications in
mice in the late 1980s and the finding that almost 99% of mouse
genes have an equivalent in humans established mice as the main
model organism for the analysis of the molecular mechanisms
underlying human diseases.
However, recently, the relevance of mice as a valuable model
organism for translational research has become increasingly
controversial. This discussion has been renewed by the study of
Seok et al (2013) that compared transcriptomic data from human
inflammatory diseases with data from mice challenged with
inflammatory stimuli and the work of Takao & Miyakawa (2015)
that reanalyzed the same datasets using different strategies and
algorithms.
Both groups strongly focused on classical gene-to-gene compar-
isons and examined the global congruency of the differentially
expressed genes. The traditional strategy to analyze transcriptomics
on a single-gene level is well justified for perturbations that have
very large impacts on individual genes and for biomarker identifi-
cation. However, these conventional approaches suffer from severe
inefficiencies because they make use of only a minor fraction of the
information contained in whole-genome transcriptomic datasets. A
major limitation is the need to set an arbitrary threshold for the
determination of differentially expressed genes (which is also a
matter of discussion in Seok et al, 2013, and Takao & Miyakawa,
2015). This requirement generally restricts the analysis to a few
highly up- and downregulated genes and completely disregards the
information from the majority of the many thousands of transcripts
detected in biological samples, thereby providing reasonable objec-
tions against biased selection. In contrast, gene set enrichment anal-
ysis (GSEA), which was established for use in metabolic studies in
the 2000s (Subramanian et al, 2005), first maps all detected unfil-
tered transcripts to the intended pathways (or other “sets of inter-
est”) to allow the analysis of thousands of transcripts potentially
involved in the concerted regulation of specific pathways. GSEAs
also include moderately regulated (and nonregulated) genes that
would otherwise be lost due to experimental background noise.
Additionally, to identify regulated signaling pathways, a statistical
evaluation is subsequently performed using running sum statistics.
Importantly, this approach is fundamentally different from assigning
Gene Ontology (GO) terms or pathways to genes after filtering for
strongly regulated genes and avoids the problems associated with
cutoff values. Using this strategy, we analyzed the human and
murine datasets used by Seok et al (Table 1 in Seok et al, 2013)
and focused on pathways that were specifically assigned to
inflammatory processes. We identified and compared pathways that
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were regulated in either human or mouse studies and determined
whether the regulation of inflammatory pathways in one model
(e.g., human) could be predicted by a second model (e.g., mouse).
Finally, this strategy facilitated the identification of the optimal
mouse model for translational research of severe inflammatory
disorders.
Results
Correlation of inflammatory pathway analysis: human–human,
mouse–mouse, and human–mouse comparisons
First, we applied GSEA to identify the relevant signaling pathways.
We included expression data for all transcripts, thereby avoiding
biased filtering of a few highly regulated genes. Because mouse
models aim to mimic a specific disorder using different experimental
manipulations (i.e., severe inflammatory diseases), we specifically
focused on pathways involved in immunological processes anno-
tated by the BioCarta, Reactome, and Kyoto Encyclopedia of Genes
and Genomes (KEGG) databases. Then, we compared the pathway
regulation profiles between the human–human, mouse–mouse, and
human–mouse datasets.
The human datasets correlated very well with one another, with
average positive and negative predictive values of 61% (Fig 1A) that
represented a 35% increase against overlap by chance (Fig EV1). A
total of 96% of the human–human comparisons showed significant
correlations in their pathway activities (P < 0.05). However, various
distinct mouse datasets showed only slight intraspecies correlations
in inflammatory pathway regulation, with average positive and
negative predictive values of 44% (11% increase against overlap by
chance). A total of 47% of the mouse–mouse correlations were
statistically significant (Figs 1A and EV1). Moreover, both the
congruency of pathway regulation within one species and the
number of significantly correlating pathways within one species
were species dependent (P ≤ 0.0001, Figs 1A and EV1).
Strikingly, analysis of the overlap between all human and
mouse datasets revealed average positive and negative predictive
values of 48% (representing a 19% increase against overlap by
chance), and 57% of human–mouse comparisons showed
significant correlations (P < 0.05) (Figs 1A and EV1). These find-
ings indicate that certain mouse models have the potential to
mimic human inflammatory signaling processes much better than
others.
Identification of mouse models with high predictivity for
human sepsis
The comparison of inflammatory pathway regulation demonstrated
high diversity in the degrees of their correlation that could likely be
attributed to the diverse etiology and/or treatment protocols under-
lying inflammatory diseases. As depicted in Fig 1B, a subgroup of
mouse models correlated very well with most human studies, with
average positive and negative predictive values of 62% and an aver-
age 32% increase against overlap by chance (dotted line). This
result comprises infection models induced by Staphylococcus aureus
injection (intravenous or intraperitoneal) or cecal ligation and punc-
ture (CLP), in concordance with previous reports (Buras et al, 2005;
Fink, 2008). In contrast, studies based on intoxication by
lipopolysaccharide (LPS) gavage or intratracheal injection of Strepto-
coccus pneumoniae showed no correlation with the selected human
septic models (Fig 1B), raising questions as to the applicability of
these mouse models to mimic systemic inflammatory disorders
(Buras et al, 2005; Fink, 2008).
Identification of inflammatory pathways shared between human
and mouse models
We identified the underlying inflammatory pathways that were
collectively induced in the selected human and mouse models
(Fig 1B, dotted line). The shared pathways included FccR-mediated
phagocytosis, Toll-like receptor pathways, interleukin-6 and inter-
leukin-1 receptor pathways, and the complement cascade (Fig 2 and
Appendix Fig S1). Strikingly, modulators of these signaling path-
ways have recently been translated into promising clinical trials
against conditions such as psoriasis (Hennessy et al, 2010; Brennan,
2014), rheumatoid arthritis (Jones et al, 2010), and delayed graft
functions (Hennessy et al, 2010), among others (Dinarello et al,
2012).
Discussion
Animal models have long been used for determining disease mecha-
nisms and drug discovery (Bolker, 2012). Low success in clinical
trials, particularly in the field of sepsis therapy, led to skepticism
regarding the predictivity of animal models (Cohen et al, 2015).
Additionally, controversial discussions were provoked by the very
different conclusions drawn from the same data after applying dif-
fering data analysis strategies (Seok et al, 2013; Shay et al, 2015;
Takao & Miyakawa, 2015; Warren et al, 2015). Thus, robust and
reliable bioinformatics techniques are needed for the analysis of
complex “omics” data to systematically identify the optimal animal
model for a given human disorder. Notably, an optimal model
assessment contributes to animal welfare because it can help avoid
overinterpretation and unnecessary repetition of animal experiments
that might not correlate with the human situation.
One major critique of the data analysis strategy proposed by
Takao & Miyakawa (2015), which concluded that “genomic
responses in mouse models greatly mimic human inflammatory
diseases”, was the restriction to a few genes that were differentially
expressed in both species (Warren et al, 2015). We extended this
strategy to additional human and mouse datasets (Table 1 in Seok
et al, 2013) that were not considered by Takao and Miyakawa. The
correlation analysis confirmed significant correlations for most of
the intra- and interspecies comparisons (121 out of 137 with
P < 0.05, Appendix Fig S2). Apparently, the single-gene approach
used by Takao and Miyakawa tended to overestimate the correla-
tions between mouse and human data because only overlapping
differentially expressed genes were compared to one another, and all
relevant information from the other genes involved in inflammation
was skipped. Consequently, this approach did not allow the identifi-
cation of mouse models that better mimicked human disease.
Notably, this data-handling strategy is not appropriate for multiple
hypothesis correction because it will yield very few genes for some
dataset correlations. These limitations and the discrepancy between
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Figure 1. Identification of inflammatory mouse models that show high correlation with human diseases.
The regulation of inflammatory pathways was assessed by gene set enrichment analysis (GSEA) using unfiltered gene expression data from 8 human and 9 mouse
studies.
A Significantly regulated pathways were compared between two datasets from human (h) and/or mouse (m) studies. The degree of pathway overlap is depicted as the
mean predictive values between these two datasets. Studies that revealed pathway overlap significantly greater than that expected by chance (P ≤ 0.05) are labeled
with green triangles. The numbers of significantly correlated studies are given below the datasets. Lines indicate the mean  95% confidence interval. The P-values
for each pair of datasets were calculated using a chi-squared test, and the P-values for the comparison of species effects were calculated using the Kruskal–Wallis
test followed by Dunn’s multiple comparisons test and Bonferroni correction.
B Correlation matrix of pathway comparisons among human and mouse inflammatory studies. The overlap of pathway regulation is shown as the average change in
the positive and negative predictive value over expectation by chance (blue, decrease, low correlation; red, increase, high correlation). The comparison of human with
murine datasets revealed a subgroup of experimental murine models that were highly correlative to human clinical studies (dotted line), consisting of the
Staphylococcus aureus injection and the cecal ligation and puncture (CLP) models. In contrast, lipopolysaccharide (LPS) gavage and intratracheal infection with
Streptococcus pneumoniae showed no correlation to human inflammatory diseases.
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Figure 2. Identification of regulated signaling pathways shared between human inflammatory diseases and selected mouse models.
The datasets were from the subgroup of experimental murine models that were highly correlative to human clinical studies. Regulation of inflammatory pathways
was determined by GSEA and is visualized according to the normalized enrichment score (blue, decreased expression, FDR ≤ 0.25; red, increased expression, FDR ≤ 0.25; white,
pathway not detectable or not changed, FDR > 0.25).
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the opposite conclusions drawn by Seok et al (2013), who concluded
that a poor correlation existed between humans and mice, disclose a
strong need for more standardized and unbiased data analysis
strategies.
Gene set enrichment analysis overcomes the aforementioned limi-
tations of traditional gene-to-gene interpretations because it makes
use of a “no-cutoff” strategy by including all experimental informa-
tion, irrespective of the magnitude of the signal changes. Thus, GSEA
avoids arbitrary factors during gene selection and includes informa-
tion from the majority of the many thousands of transcripts detected
in biological samples (da Huang et al, 2009). After assigning the
detected transcripts to biological pathways, GSEA uses nonparamet-
ric Kolmogorov–Smirnov enrichment statistics to estimate the regu-
lation of these pathways. These set enrichment approaches have
been shown to be more robust for comparisons of transcriptomic
data between different platforms or with different experimental
models or clinical cohorts (Spinelli et al, 2015). Therefore, these
approaches are currently recommended for data analysis for human
risk assessment of chemicals and may lead to reductions in animal
use in toxicological research (National Research Council (US), 2007;
Pielaat et al, 2013; European Food Safety Authority, 2014). Using
GSEA, we were able to identify particular mouse models (i.e.,
Staphylococcus aureus injection and the CLP model) that showed
inflammatory pathway regulation profiles that were similar to the
human situation; notably, most of these pathways are currently
promising clinical targets in several inflammatory disorders. Never-
theless, from the clinical outcome, it is known that sepsis (in
contrast to other inflammatory disorders) is a complex syndrome
involving both pro-inflammatory (early phase) and anti-inflammatory
(later phase) responses (Hotchkiss et al, 2009). Addressing this
complex biphasic pathogenesis may require more than suppression
of the pro-inflammatory processes. Instead, recent studies have
indicated that inhibiting the sepsis-induced apoptosis of immune
cells that caused lethal immunosuppression was the appropriate
strategy for the treatment of severe sepsis (Hotchkiss & Opal,
2010; Fink & Warren, 2014). Taking the complex biphasic patho-
genesis of sepsis into consideration, the recruitment of participants
and the selection of adequate time points to define the septic
model are of high importance. The same is true for the preclinical
murine model.
We agree with Warren et al (2015) that drugs physically work at
the molecular level (e.g., by binding to specific proteins). However,
increasing evidence from genetic and molecular biology studies has
shown that cellular processes and pathways are generally not
affected by the alteration of a single gene or protein but instead are
the result of alterations to a group of interacting proteins. This issue
highlights the importance of analyzing signaling networks involved
in diseases and their underlying biological processes (Yu et al,
2015). Consequently, the current pharmacological strategy is to
modulate a specific pathway or parts of a pathway involved in
immune processes, and pathway-focused strategies are valuable
approaches for the identification of relevant therapeutic targets. The
proceeding steps inevitably include the definition of possible key
players in the relevant pathways. We were able to identify a list of
genes involved in the Toll-like receptor cascade (Reactome) path-
way (Table EV1) that were upregulated in at least 9 of 11 datasets
where the human and mouse inflammatory studies were signifi-
cantly correlated. For instance, congruently upregulated genes
included the CD14 molecule, the lipopolysaccharide-binding protein
(LBP), and the Toll-like receptors (TLRs) 2, 4, 6, and 8. CD14 is an
accessory receptor for TLRs, and ongoing clinical trials indicate that
CD14 inhibition is a promising strategy to treat sepsis (Verbon et al,
2001; Egge et al, 2015). Furthermore, LBP is an acute-phase
biomarker for sepsis (Schumann & Zweigner, 1999), and the TLR
family was recently reported to be a promising target for the treat-
ment of sepsis (Savva & Roger, 2013).
Seok et al (2013) and Takao & Miyakawa (2015) analyzed the
treatment or disease effects at the genome-wide level to evaluate
the capacity of mouse models to mimic human inflammatory
diseases. Despite the given limitations (Shay et al, 2015), such as
the differing cellular compositions (i.e., lymphoid to myeloid
ratio) of humans and mice, and the treatment effects in humans
that were ignored, the aim of both studies was to gain a deeper
understanding of the conserved effects between humans and mice
on the molecular level. Notably, most of these candidate genes
are excluded from traditional gene-to-gene analyses due to their
moderate expression changes. Therefore, the gene set enrichment
analysis presented here offers a valuable tool for drug target
identification.
Using GSEA, we were able to provide more detailed information.
We can certainly conclude that biologically relevant parts of
“genomic responses in mouse models mimic human inflammatory
diseases” (Seok et al, 2013; Takao & Miyakawa, 2015) despite these
limitations in the datasets. Our analysis supports the assumption
that the identification of new pharmacological targets for the treat-
ment of inflammatory diseases does not necessarily require the
complete comparison of the whole transcriptomes of human
samples with the transcriptomes from mouse models (as also
discussed by Shay et al, 2015). Instead, it is likely imperative for
pharmacological target identification to focus on a particular
(patho)physiological process. Therefore, it is necessary (i) to
identify regulated pathways and molecules that are exactly shared
between the given human disorder and experimental mouse models
and (ii) to identify the best mouse model for that human disorder
(e.g., burn or sepsis). We emphasize that the GSEA approach will
not overcome some basic difficulties in developing the appropriate
animal model before any (transcript)omics data have been gener-
ated from this model. Generally, similar agents are used in both
humans and mice to induce diseases with similar phenotypes. The
same holds true for the introduction of genetic defects that target
species homologs. This phenomenon does not reflect the possible
variety of outcomes resulting from the diversity of biological
processes across species barriers (i.e., mechanisms of adaptation,
different pharmacokinetics upon gene deletion or treatment with
similar triggers/inducers). Importantly, GSEA is not a tool to predict
how to a priori design new model systems, but it is an effective tool
to decide how to interpret existing data in a standardized manner,
which might add value to the careful selection of the correct animal
model and might avoid unnecessary and misleading translational
studies.
Currently, 241 mouse strains are available at The Jackson Labora-
tories to investigate “infectious diseases”. This number reflects only
a small fraction of all inflammatory mouse models that are either
experimentally induced or genetically modified. Inbred mouse
strains that provide a basis for subsequent disease models are highly
divergent in their immune response patterns as a result of genetic
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mutations and polymorphisms (Sellers et al, 2012). Knowledge of
these genetic profiles is essential for the accurate selection of disease
models. Therefore, adequate model assessment is one of the most
critical factors for success in translational research for the selection
of either already existing disease models or the appropriate labora-
tory strain genetic background to facilitate further disease model
development. We believe that the use of previously published data-
sets, ongoing discussions on experimental improvements (Shay
et al, 2015), as well as targeted strategies for model assessment and
the gene set enrichment analyses described here have great potential
to systematically define the optimal mouse model and protocol for a
given human disorder (and are not restricted to immunological
studies). These resources should be increasingly used to improve
the success of translational research and to reduce the number of
animal studies. Indeed, the recent debate concerning failed clinical
trials linked to inappropriate animal models demands a re-evaluation
of the respective mouse models and the utilization of the
growing availability of transcriptomics data and systems biology
approaches.
The current discussion on different approaches and algorithms
clearly discloses a general limitation of genomic studies: the bioin-
formatics analyses are not well standardized, and the resulting
conclusions are prone to bias. If the same sets of experimental data
can lead to diametrically opposite conclusions, then the relevance
and outcome of genomic (and other “omics”) studies for purposes
other than explorative approaches are negligible and strongly
require improvement. Thus, better standardization of statistical
analyses and data interpretation are urgently needed and should be
addressed to improve the use of omics data for regulatory purposes
(National Research Council (US), 2007; Pielaat et al, 2013; European
Food Safety Authority, 2014).
The novelty of our approach encompasses several key aspects.
First, by using a GSEA approach instead of a single-gene analysis, it
is possible to circumvent any problems associated with the subjec-
tive setting of gene expression thresholds and gene filtering, which
led to opposite conclusions by Seok et al (2013) vs. Takao and
Miyakawa (2015), and to enable analysis in an unbiased, standard-
ized manner. Second, by using pathway-based GSEA, the focus is
exclusively on genes annotated as involved in inflammatory
processes, thereby specifically addressing the (patho)physiological
process of the question. Third, our approach is able to identify
(already existing) mouse models that have high predictivity for the
human condition of interest, thereby reducing unnecessary animal
studies while increasing success in translational research.
Materials and Methods
Datasets for human diseases and mouse models
The datasets used in this study were the same as those selected by
Seok et al (2013). The transcriptomic data were downloaded from
the gene expression omnibus (GEO) database and consisted of 8
human and 9 mouse studies. Accession numbers and details are
listed in Appendix Table S1. If different time points were available,
one was arbitrarily chosen as indicated in Appendix Table S1.
GSE10474 (human ARDS) and GSE19030 (mouse ARDS) were
excluded due to the lack of healthy controls.
Gene set enrichment analysis (GSEA)
The GSEA approach (Subramanian et al, 2005) was used to system-
atically analyze the transcriptomic data modulation of inflammatory
pathways. GSEA allows the detection of congruent changes in gene
expression for a defined pathway and thus is sensitive to slight
alterations in pathway regulation irrespective of the differential
expression of particular genes. Disease/treatment groups were
always compared to the corresponding control groups. Mouse gene
symbols were collapsed to Human Genome Organization (HUGO)
symbols in the GSEA tool. Inflammatory pathways (95 in total) were
manually downloaded from the BioCarta, Reactome, and KEGG
databases (Dataset EV1). GSEA was performed with the following
parameters: 1,000 gene set permutations, weighted enrichment
statistics, gene set size between 15 and 500, and signal-to-noise
metrics. Regulated pathways were considered statistically significant
if the false discovery rate (FDR) was ≤ 0.25. The GSEA-derived
normalized enrichment score was used for the visualization of
pathway regulation.
Comparison of pathway regulation
Building on the GSEA results, there were three possible outcomes
for pathway regulation: (i) the pathway was significantly upregu-
lated with an FDR ≤ 0.25, (ii) the pathway was significantly down-
regulated with an FDR ≤ 0.25, or (iii) the pathway was not changed
(FDR > 0.25) or too few genes in that pathway were detectable. The
regulation of inflammatory pathways was compared between two
datasets (models) in each case by calculating the positive and
negative predictive values. This approach was used to investigate
whether the pathway regulation of model 1 could be predicted by
model 2. Thus, the positive predictive value was estimated by the
number of overlapping upregulated pathways in models 1 and 2
divided by the total number of pathways upregulated in model 2.
Correspondingly, the negative predictive value was estimated by
the number of overlapping downregulated pathways in models 1
and 2 divided by the total number of pathways downregulated in
model 2.
Positive and negative predictive values were compared to the
values expected by chance. For instance, if 10% of the pathways
were upregulated in model 1 as defined above, the positive predic-
tive value to model 2 would be 10% if the regulation processes in
both models were independent from one another. This approach
allows the estimation of the amount of information that can be
gained from model 2 regarding model 1. A chi-squared test was
performed to estimate the statistical significance of the prediction
calculation. This test is based on a three by three contingency table,
which represents all three possible outcomes of the pathway analy-
sis. Thus, all inflammatory pathways and all genes belonging to
these pathways were considered in the analysis. As a consequence,
the analyses included all genes assigned to the inflammatory path-
ways, and no biased filtering of highly up- or downregulated genes
was required.
To determine the statistically significant differences in intraspeci-
fic pathway correlations between humans and mice, the Kruskal–
Wallis test followed by Dunn’s multiple comparisons test and
Bonferroni correction were performed using the R package FSA
function. Furthermore, a two-sample test for the equality of
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proportions with continuity correction was performed on the
species-related number of significantly correlated pathways using
the R function prop.test.
Expanded View for this article is available online.
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